JP2002508003A - 新規な組成物 - Google Patents
新規な組成物Info
- Publication number
- JP2002508003A JP2002508003A JP50818599A JP50818599A JP2002508003A JP 2002508003 A JP2002508003 A JP 2002508003A JP 50818599 A JP50818599 A JP 50818599A JP 50818599 A JP50818599 A JP 50818599A JP 2002508003 A JP2002508003 A JP 2002508003A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- blocker
- pindolol
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 29
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract description 26
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract description 26
- 239000002876 beta blocker Substances 0.000 claims abstract description 23
- 229940097320 beta blocking agent Drugs 0.000 claims abstract description 23
- 239000012730 sustained-release form Substances 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 14
- 229960002508 pindolol Drugs 0.000 claims description 22
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical group CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 21
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 11
- 229960002296 paroxetine Drugs 0.000 claims description 11
- 238000013268 sustained release Methods 0.000 claims description 10
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 235000003642 hunger Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 201000009032 substance abuse Diseases 0.000 claims description 4
- 231100000736 substance abuse Toxicity 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002969 morbid Effects 0.000 claims 3
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 229940009505 paroxetine hydrochloride 20 mg Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 239000008188 pellet Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003094 Methocel™ K4M Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9714675.7 | 1997-07-11 | ||
| GBGB9714675.7A GB9714675D0 (en) | 1997-07-11 | 1997-07-11 | Novel composition |
| PCT/EP1998/004971 WO1999002142A2 (fr) | 1997-07-11 | 1998-07-07 | Nouvelle composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002508003A true JP2002508003A (ja) | 2002-03-12 |
Family
ID=10815744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50818599A Pending JP2002508003A (ja) | 1997-07-11 | 1998-07-07 | 新規な組成物 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0996466A2 (fr) |
| JP (1) | JP2002508003A (fr) |
| KR (1) | KR20010021644A (fr) |
| CN (1) | CN1262627A (fr) |
| AP (1) | AP2000001728A0 (fr) |
| AR (1) | AR016128A1 (fr) |
| AU (1) | AU9340198A (fr) |
| BG (1) | BG104119A (fr) |
| BR (1) | BR9810996A (fr) |
| CA (1) | CA2295822A1 (fr) |
| CO (1) | CO4950552A1 (fr) |
| DZ (1) | DZ2556A1 (fr) |
| EA (1) | EA200000112A1 (fr) |
| GB (1) | GB9714675D0 (fr) |
| HU (1) | HUP0003074A3 (fr) |
| ID (1) | ID24191A (fr) |
| IL (1) | IL133869A0 (fr) |
| MA (1) | MA24604A1 (fr) |
| NO (1) | NO20000107L (fr) |
| OA (1) | OA11276A (fr) |
| PE (1) | PE99699A1 (fr) |
| PL (1) | PL338017A1 (fr) |
| SK (1) | SK72000A3 (fr) |
| TR (1) | TR200000074T2 (fr) |
| WO (1) | WO1999002142A2 (fr) |
| ZA (1) | ZA986138B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| PL205109B1 (pl) | 1998-11-02 | 2010-03-31 | Elan Pharma Int Ltd | Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie |
| ATE526950T1 (de) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | Hydrocodon-formulierungen mit gesteuerter freisetzung |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| EP2263658A1 (fr) | 2000-10-30 | 2010-12-22 | Euro-Celtique S.A. | Formulations d'hydrocodone à liberation lente |
| EP1793818A2 (fr) * | 2004-09-17 | 2007-06-13 | Neurocure Ltd. | Pindolol pour le traitement du syndrome et du trouble dysphorique premenstruel |
| CN100469356C (zh) * | 2006-09-08 | 2009-03-18 | 山东益康药业有限公司 | 复方阿替洛尔缓释片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2732335C2 (de) * | 1976-07-27 | 1983-01-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten |
| CA2134038C (fr) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentialisation des effets de medicaments |
| EP0714663A3 (fr) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A |
| ES2145977T3 (es) * | 1995-08-16 | 2000-07-16 | Lilly Co Eli | Potenciacion de la respuesta de la serotonina. |
| EP0792649A1 (fr) * | 1996-02-29 | 1997-09-03 | Eli Lilly And Company | Traitement de l'insomnie |
-
1997
- 1997-07-11 GB GBGB9714675.7A patent/GB9714675D0/en active Pending
-
1998
- 1998-07-07 CN CN98806975A patent/CN1262627A/zh active Pending
- 1998-07-07 EA EA200000112A patent/EA200000112A1/ru unknown
- 1998-07-07 HU HU0003074A patent/HUP0003074A3/hu unknown
- 1998-07-07 CA CA002295822A patent/CA2295822A1/fr not_active Abandoned
- 1998-07-07 EP EP98946294A patent/EP0996466A2/fr not_active Withdrawn
- 1998-07-07 KR KR1020007000202A patent/KR20010021644A/ko not_active Application Discontinuation
- 1998-07-07 WO PCT/EP1998/004971 patent/WO1999002142A2/fr not_active Application Discontinuation
- 1998-07-07 SK SK7-2000A patent/SK72000A3/sk unknown
- 1998-07-07 ID IDW20000035A patent/ID24191A/id unknown
- 1998-07-07 BR BR9810996-0A patent/BR9810996A/pt not_active Application Discontinuation
- 1998-07-07 JP JP50818599A patent/JP2002508003A/ja active Pending
- 1998-07-07 AU AU93401/98A patent/AU9340198A/en not_active Abandoned
- 1998-07-07 TR TR2000/00074T patent/TR200000074T2/xx unknown
- 1998-07-07 PL PL98338017A patent/PL338017A1/xx unknown
- 1998-07-07 AP APAP/P/1999/001728A patent/AP2000001728A0/en unknown
- 1998-07-07 IL IL13386998A patent/IL133869A0/xx unknown
- 1998-07-08 DZ DZ980166A patent/DZ2556A1/fr active
- 1998-07-10 ZA ZA9806138A patent/ZA986138B/xx unknown
- 1998-07-10 CO CO98039260A patent/CO4950552A1/es unknown
- 1998-07-10 PE PE1998000612A patent/PE99699A1/es not_active Application Discontinuation
- 1998-07-10 MA MA25165A patent/MA24604A1/fr unknown
- 1998-07-10 AR ARP980103371A patent/AR016128A1/es unknown
-
2000
- 2000-01-10 NO NO20000107A patent/NO20000107L/no not_active Application Discontinuation
- 2000-01-11 OA OA1200000006A patent/OA11276A/en unknown
- 2000-02-01 BG BG104119A patent/BG104119A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1262627A (zh) | 2000-08-09 |
| BG104119A (en) | 2000-12-29 |
| HUP0003074A2 (hu) | 2001-01-29 |
| WO1999002142A2 (fr) | 1999-01-21 |
| KR20010021644A (ko) | 2001-03-15 |
| NO20000107D0 (no) | 2000-01-10 |
| AP2000001728A0 (en) | 2000-03-31 |
| AU9340198A (en) | 1999-02-08 |
| WO1999002142A3 (fr) | 1999-04-15 |
| PE99699A1 (es) | 1999-12-21 |
| HUP0003074A3 (en) | 2001-12-28 |
| OA11276A (en) | 2003-07-31 |
| NO20000107L (no) | 2000-01-10 |
| PL338017A1 (en) | 2000-09-25 |
| EP0996466A2 (fr) | 2000-05-03 |
| EA200000112A1 (ru) | 2000-10-30 |
| CA2295822A1 (fr) | 1999-01-21 |
| SK72000A3 (en) | 2000-12-11 |
| CO4950552A1 (es) | 2000-09-01 |
| ID24191A (id) | 2000-07-13 |
| ZA986138B (en) | 2000-01-10 |
| GB9714675D0 (en) | 1997-09-17 |
| MA24604A1 (fr) | 1999-04-01 |
| AR016128A1 (es) | 2001-06-20 |
| IL133869A0 (en) | 2001-04-30 |
| TR200000074T2 (tr) | 2000-05-22 |
| DZ2556A1 (fr) | 2003-02-15 |
| BR9810996A (pt) | 2000-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200038344A1 (en) | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | |
| KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| JP6169411B2 (ja) | ゾニサミドの徐放性製剤 | |
| US6221394B1 (en) | Dosage forms | |
| US7569612B1 (en) | Methods of use of fenofibric acid | |
| US20050250838A1 (en) | Formulation for sustained delivery | |
| US20110189269A1 (en) | Extended release composition containing tramadol | |
| JP2013530220A (ja) | ダポキセチンを含む時間差徐放性経口投与型の薬学的組成物 | |
| EA014294B1 (ru) | Комбинация снотворного агента длительного действия и снотворного агента короткого действия | |
| JPH11509539A (ja) | パロキセチン制御放出組成物 | |
| WO2008070072A2 (fr) | Formes, compositions de carvédilol, et leurs procédés de préparation | |
| AU703242B2 (en) | Film coated tablet of paracetamol and domperidone | |
| WO2010128525A2 (fr) | Préparation d'ivabradine dans le traitement des maladies cardiovasculaires | |
| KR20170134393A (ko) | 테소펜신, 베타 차단제 복합 제형 | |
| US20070269510A1 (en) | Solid Unit Dosage Forms of 5-Ht1 Agonist | |
| JP2002508003A (ja) | 新規な組成物 | |
| CN112618505B (zh) | 一种宠物用含有贝那普利和匹莫苯丹的复方药物组合物及其制备方法 | |
| US7767227B2 (en) | Galenical form for oral administration with prolonged release of molsidomine | |
| CZ200081A3 (cs) | Nový přípravek | |
| MXPA00000416A (en) | Novel composition | |
| JP2002518330A (ja) | 処置方法 | |
| TW201626990A (zh) | 含有褪黑激素和舍曲林的口服複合錠劑 | |
| US20090162431A1 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| WO2015150948A1 (fr) | Compositions pharmaceutiques orales solides à libération modifiée de cyclobenzaprine ou d'un sel de cette dernière | |
| KR20090104785A (ko) | 안정한 서방출형의 경구 투여용 조성물 |